Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302685 | 0.90 | MEN1 (1.00) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL5623889 | 0.85 | MEN1 (0.88) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL2542317 | 0.84 | MEN1 (0.56) | MEN1KMT2AMAOARAB9AMAOB | |
| SCHEMBL8945322 | 0.83 | KMT2A (0.85) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL12928357 | 0.81 | MEN1 (0.81) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL19439086 | 0.81 | MEN1 (0.81) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL8945706 | 0.81 | MEN1 (0.81) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL10013782 | 0.81 | MEN1 (0.81) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL5623546 | 0.81 | MEN1 (0.81) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL1495914 | 0.80 | MEN1 (0.79) | MEN1KMT2AHSD17B10SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | MEN1 1981/4885KMT2A 423/4885HSD17B10 836/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | MEN1 1602/4885KMT2A 552/4885HSD17B10 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.